A recurrent ERCC3 truncating mutation confers moderate risk for breast cancer Academic Article uri icon

Overview

MeSH Major

  • Models, Biological
  • Neoplasms
  • Neoplastic Stem Cells

abstract

  • A functionally significant recurrent ERCC3 mutation increased the risk for breast cancer in a genetic isolate. Mutated cell lines showed lower survival after in vitro exposure to DNA-damaging agents. Thus, similar to tumors arising in the background of homologous repair defects, mutations in nucleotide excision repair genes such as ERCC3 could constitute potential therapeutic targets in a subset of hereditary breast cancers. Cancer Discov; 6(11); 1267-75. ©2016 AACR.This article is highlighted in the In This Issue feature, p. 1197.

publication date

  • November 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5614601

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-16-0487

PubMed ID

  • 27655433

Additional Document Info

start page

  • 1267

end page

  • 1275

volume

  • 6

number

  • 11